Anthropic quietly sets up biology lab as it ramps – Business News
SAN FRANCISCO, Sept 18 – Anthropic has quietly set up a laboratory to do bodily biology work as it pushes its artificial-intelligence ambitions into the world of drug science.
At a time when fears of AI are gripping the public, the startup has constructed a moist lab, or place for bodily experiments, within the San Francisco Bay Area, two people aware of the matter mentioned.
Anthropic has mentioned it needs to unlock remedies for uncommon illnesses, and its biology work has gone past “in silico” or laptop evaluations.
CEO of Anthropic Dario Amodei attends a working lunch with G7 leaders, G7 outreach companions, and world tech CEOs on innovation and AI during the G7 Summit on June 17, 2026, in Évvian-les-Bains, France. Getty Images
In a Reuters interview on Tuesday, Anthropic’s head of life sciences, Eric Kauderer-Abrams, confirmed the startup’s moist lab.
“We believe that to do biology, the final test is still and will be for a while in real lab work,” he mentioned.
“We absolutely are doing that today, and I would describe our approach as being typical of what you would see in most biotech companies, where there’s some amount of that that we’re doing in our own facilities and some amount of that that we’re working with external partners on.”
A spokesperson later clarified that Anthropic’s lab just isn’t for drug discovery particularly, declining to elaborate.
The transfer represents a small step towards Anthropic’s monumental ambition to deal with illnesses that it thinks the pharmaceutical industry is neglecting — and to take action earlier than employees and the public lose religion that AI justifies erasing jobs and probably human life, one of the people mentioned.
The success of any drug program it runs just isn’t sure; most medication fail to move trials for medical security and efficacy.
For Anthropic CEO Dario Amodei, the trouble is personal. A illness killed his father solely a few years earlier than a remedy took place, he mentioned in a latest essay. Kauderer-Abrams echoed the sentiment.
“The mission of the company is to develop powerful AI in such a way that benefits the world,” Kauderer-Abrams mentioned. “By far, we see the biggest opportunity for that in the life sciences, and that is motivating everything that we’re doing.”
Balancing ambition with fears of disaster
Like different biotech firms, Anthropic is embracing bodily automation, mentioned the 2 people, who spoke on situation of anonymity.
The startup needs to push how its Claude AI can direct robotic models to hold out science experiments with restricted human intervention, one of the people mentioned.
Still, Anthropic believes that human oversight and involvement are important for security, its spokesperson mentioned.
“We’re in the very early innings of using AI to automate the execution of lab work,” mentioned Kauderer-Abrams, “an area that has the potential to bring about meaningful acceleration in so many different processes.”
Anthropic’s race to use quickly evolving technology to a biology lab comes at an extraordinary time for the company.
In the previous two weeks, some of its researchers warned that AI may result in human extinction, and Anthropic mentioned it discovered examples the place its systems may have been used towards organic weapons development, which met some skepticism.
Amodei additionally referred to as for a development slowdown, saying that a future AI more succesful than the OpenAI brokers that hacked Hugging Face may trigger catastrophic harm.
At the identical time, Anthropic is getting ready to go public in a doubtlessly $2 trillion IPO to raise more money for such AI development.
“In our life-science work, we’re always balancing these things,” Kauderer-Abrams mentioned, “making models better in ways that we think will uplift and accelerate developing medicines, and being thoughtful and careful about how we deploy it to limit the risk.”
Procurement ramp-up
Anthropic staked out its intention to begin working drug packages, at a San Francisco occasion in June. On stage there, Kauderer-Abrams mentioned Anthropic would do preclinical work in areas that conventional firms didn’t discover enticing financially.
The company additionally launched software program referred to as Claude Science, and it earlier added Novartis NOVN.S CEO Vas Narasimhan to its board and purchased the startup Coefficient Bio for about $400 million in stock, in accordance with media stories.
Anthropic confirmed the acquisition, which can help it construct instruments for drug development, however it had no touch upon the deal price.
Anthropic launched software program referred to as Claude Science. NurPhoto through Getty Images
Now, Anthropic is bulking up its in-house lab efforts for velocity and for firsthand expertise in biology, although it outsources work when environment friendly, Kauderer-Abrams advised Reuters.
“There’s some things that we can do much faster in our own hands,” he mentioned, with the purpose “to operate at the largest possible scale.”
Anthropic has seemed to rent a chief who may ramp up procurement and different operations, it mentioned in a latest LinkedIn job post.
Another Anthropic function solicited through Jobera sought an skilled on “protein and nucleic acid characterization,” amongst different biochemical work. A 3rd Anthropic job itemizing learn: “Our goal is to speed up progress in the life sciences by an order of magnitude.”
Life sciences already represents one of Anthropic’s greatest investment areas by headcount and sources, Kauderer-Abrams mentioned.
Targeting ‘undruggable’ circumstances
His view is that AI may fast-track development for circumstances beforehand regarded as “undruggable” — too troublesome to deal with.
The technology may velocity discovery, as an illustration, of bispecific and trispecific antibodies, complicated molecules that may be directed at a number of factors on a focused protein or cell, or hit a number of targets.
The exact illnesses Anthropic is addressing and its progress stay unclear. Once a molecule is recognized, it can take years to convey a drug to market as it is examined in human trials, a problem that Anthropic has not taken on.
Start your day with all you need to know
Morning Report delivers the newest information, videos, images and more.
Thanks for signing up!
Isomorphic Labs, the drug discovery arm of rival Alphabet GOOGL.O, has labored for years to get to the clinic and earlier delayed that purpose to the tip of 2026.
In its efforts at lab and different industry automation, Anthropic launched the Model Hardware Standard in August, which helps AI operate tools.
A release out of academia referred to as PyLabRobot, unrelated to Anthropic, earlier addressed associated although completely different automation wants.
Anthropic is offering work just like the Model Hardware Standard and broader AI companies and instruments to all method of high pharmaceutical firms, such as Roche’s ROPC.S Genentech, Bristol Myers Squibb BMY.N and Novo Nordisk NOVOb.CO.
At the identical time, Anthropic is navigating a trust drawback, the 2 people aware of its efforts mentioned. Its prospects could fear that Anthropic will study from their competing drug packages, even as the AI startup partitions off their knowledge from view.
Kauderer-Abrams mentioned that Anthropic, due partly to competitors issues, has set a boundary that it just isn’t working medical trials for now and is specializing in wants that industry wouldn’t tackle.
“We’re not competing with pharma and biotech companies that make their business in bringing drugs to market,” he mentioned.
